Equillium (NASDAQ:EQ) Stock Price Up 1.1%

Equillium, Inc. (NASDAQ:EQ)’s share price traded up 1.1% during trading on Thursday . The stock traded as high as $1.85 and last traded at $1.81. 130,386 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 315,095 shares. The stock had previously closed at $1.79.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price target on Equillium from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd.

Equillium Stock Down 5.5 %

The company has a 50-day moving average price of $2.28 and a two-hundred day moving average price of $1.28.

Equillium (NASDAQ:EQ) last issued its earnings results on Monday, March 25th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.10. Equillium had a negative return on equity of 51.82% and a negative net margin of 36.96%. The company had revenue of $9.21 million during the quarter, compared to the consensus estimate of $8.85 million. As a group, research analysts expect that Equillium, Inc. will post -0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Equillium stock. Decheng Capital LLC purchased a new stake in Equillium, Inc. (NASDAQ:EQ) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,447,308 shares of the company’s stock, valued at approximately $3,215,000. Equillium comprises 0.9% of Decheng Capital LLC’s investment portfolio, making the stock its 18th largest position. Decheng Capital LLC owned about 12.66% of Equillium at the end of the most recent reporting period. 27.05% of the stock is owned by institutional investors and hedge funds.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.